Y.D. More Investments Ltd Sells 98,313 Shares of InMode Ltd. (NASDAQ:INMD)

Y.D. More Investments Ltd decreased its holdings in InMode Ltd. (NASDAQ:INMD) by 34.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 190,051 shares of the healthcare company’s stock after selling 98,313 shares during the quarter. Y.D. More Investments Ltd’s holdings in InMode were worth $4,227,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC bought a new stake in shares of InMode in the third quarter valued at about $27,000. Carmel Capital Partners LLC purchased a new stake in shares of InMode during the 3rd quarter valued at $36,000. Sunbelt Securities Inc. purchased a new stake in shares of InMode during the third quarter worth about $47,000. CWM LLC grew its position in InMode by 38.3% during the 4th quarter. CWM LLC now owns 2,454 shares of the healthcare company’s stock worth $55,000 after purchasing an additional 680 shares during the last quarter. Finally, NBC Securities Inc. purchased a new stake in shares of InMode during the third quarter valued at $79,000. 68.04% of the stock is owned by hedge funds and other institutional investors.

InMode Trading Up 0.3 %

Shares of InMode stock traded up $0.05 on Wednesday, hitting $17.24. The stock had a trading volume of 1,564,600 shares, compared to its average volume of 1,554,737. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of 7.42 and a beta of 2.16. InMode Ltd. has a 52-week low of $16.82 and a 52-week high of $48.25. The company’s 50 day moving average price is $20.13 and its 200 day moving average price is $21.43.

InMode (NASDAQ:INMD) last announced its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. InMode had a net margin of 40.22% and a return on equity of 29.80%. The firm had revenue of $126.80 million during the quarter, compared to the consensus estimate of $124.77 million. During the same quarter last year, the firm earned $0.69 earnings per share. The firm’s revenue was down 5.1% compared to the same quarter last year. Analysts predict that InMode Ltd. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on INMD shares. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research note on Tuesday, April 9th. Barclays reduced their price objective on shares of InMode from $34.00 to $33.00 and set an “overweight” rating for the company in a research report on Friday, April 12th. Finally, UBS Group lifted their price target on InMode from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 14th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $32.80.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.